Apical Access System with Universal Connector for Beating Heart LVAD Implantation

带有用于跳动心脏 LVAD 植入的通用连接器的心尖接入系统

基本信息

项目摘要

DESCRIPTION (provided by applicant): The objective of this proposal is to complete development of a long-term, universal Apical Access System (AAS) to improve clinical outcomes and expand the role of left ventricular assist device (LVAD) therapy. The treatment of end stage heart failure (HF) is the greatest challenge, both clinically and economically to the U.S. health care system today. With >800,000 people suffering with end stage HF and only 2,300 heart transplants and 4,600 LVADs implanted annually there is large a population underserved. LVAD implantation requires a major operative procedure with significant peri- and post-operative bleeding complications, mortality, and treatment costs. APK Advanced Medical Technologies, Inc. AAS System will allow current LVADs and future "Mini-VADs" to be implanted suture-less through a minimally invasive incision without placing the patient on cardiopulmonary bypass (CPB). By eliminating CPB, reducing access time and reducing bleeding, a significant and measurable impact on patient health and procedural cost will be achieved. The different components of the AAS System have been tested previously on the bench, in FEA computational models, and through acute and chronic (up to 12 weeks) animal experiments with positive results. The specific aims of the current proposal are: Phase I-Aim 1: Complete fabrication of the integrated components for the re-designed AAS System and demonstrate feasibility for LVAD therapy in acute bovine model (n=2) and human cadaver (n=2). Phase II-Aim 1: Complete the engineering development and design freeze of the LVAD AAS in compliance with Good Manufacturing Practices (GMP) specifications for a human implant quality system. Aim 2: Demonstrate safety and efficacy of the AAS System by completing risk analysis driven validation and verification testing. Testing to include: 600 Millio cycle fatigue, leakage/burst testing in pressurized hearts, Finite element analysis of anchoring components, sterilization validation and biocompatibility, anatomical fit and surgical procedure study (human cadaver, n=8), and in vivo acute (n=6), 14-day (n=6), and 30-day (n=6) in a chronic bovine model with HM II (Thoratec) and HVAD (HeartWare) devices. Successful outcomes will be quantified by metrics to include; incision size, ease of use, implantation time, blood loss, durability (fatigue on clinical-grade components), need for CPB, conformance to biocompatibility and sterilization ISO standards, and secure connection without air entrainment or leakage. Aim 3: Demonstrate long-term safety and reliability of the LVAD AAS in 30-day pre-GLP (n=2) and GLP (n=4) chronic bovine model study to support an IDE application for a clinical trial in patients with advanced heart failure receiving LVAD implantation only. The successful execution of this SBIR project will lead to development of a new clinical paradigm in the treatment of HF. Specifically the AAS will reduce surgical complexity and make LVAD therapy affordable leading to improved patient outcomes and quality of life. Ultimately, clinical acceptance to treat earlier stage HF patients and expansion into global markets can be achieved.
描述(由申请人提供):本提案旨在完成长期通用心尖入路系统(AAS)的开发,以改善临床结局并扩大左心室辅助装置(LVAD)治疗的作用。终末期心力衰竭(HF)的治疗是当今美国医疗保健系统在临床和经济上面临的最大挑战。每年有超过800,000人患有终末期HF,只有2,300例心脏移植和4,600例LVAD植入,存在大量服务不足的人群。LVAD植入需要大手术,具有显著的术中和术后出血并发症、死亡率和治疗费用。APK下载器APK下载器AAS系统将允许当前的LVAD和未来的“Mini-VAD”通过微创切口无缝合植入,而无需将患者置于心肺转流(CPB)。通过消除CPB、减少穿刺时间和减少出血,将对患者健康和手术成本产生显著且可衡量的影响。AAS系统的不同组件之前已在实验室、FEA计算模型以及急性和慢性(长达12周)动物实验中进行了测试,结果为阳性。当前提案的具体目标是:第I阶段-目标1:完成重新设计的AAS系统的集成组件的制造,并证明在急性牛模型(n=2)和人尸体(n=2)中进行LVAD治疗的可行性。第二阶段-目标1:根据人体植入物质量体系的良好生产规范(GMP)规范,完成LVAD AAS的工程开发和设计冻结。目的2:通过完成风险分析驱动的确认和验证测试,证明AAS系统的安全性和有效性。测试包括:6亿次循环疲劳、加压心脏中的泄漏/爆破试验、锚定组件的有限元分析、灭菌确认和生物相容性、解剖结构匹配和外科手术研究(人体尸体,n=8)以及使用HM II(Thoratec)和HVAD(HeartWare)器械在慢性牛模型中进行的体内急性(n =6)、14天(n=6)和30天(n=6)试验。成功结局将通过指标进行量化,包括:切口尺寸、易用性、植入时间、失血量、耐久性(临床级组件疲劳)、CPB需求、符合生物相容性和灭菌ISO标准以及牢固连接,无空气夹带或泄漏。目标3:在30天GLP前(n=2)和GLP(n=4)慢性牛模型研究中证明LVAD AAS的长期安全性和可靠性,以支持仅接受LVAD植入的晚期心力衰竭患者临床试验的IDE申请。该SBIR项目的成功执行将导致HF治疗中新的临床范例的开发。具体而言,AAS将降低手术复杂性,并使LVAD治疗负担得起,从而改善患者结局和生活质量。最终,可以实现治疗早期HF患者的临床接受度并扩展到全球市场。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jorge Hernan Jimenez其他文献

Jorge Hernan Jimenez的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jorge Hernan Jimenez', 18)}}的其他基金

Wireless ultrasonic powering and monitoring of Left Ventricular Assist Devices through the Internet of Medical Things
通过医疗物联网对左心室辅助装置进行无线超声波供电和监测
  • 批准号:
    10007683
  • 财政年份:
    2020
  • 资助金额:
    $ 52.57万
  • 项目类别:
Enabling of a Wireless and Remotely Monitored Deep Brain Stimulation System through the Internet of Medical Things for Parkinson's Disease Patients
通过医疗物联网为帕金森病患者启用无线和远程监控的深部脑刺激系统
  • 批准号:
    9908204
  • 财政年份:
    2019
  • 资助金额:
    $ 52.57万
  • 项目类别:
Apical Access System with Universal Connector for Beating Heart LVAD Implantation
带有用于跳动心脏 LVAD 植入的通用连接器的心尖接入系统
  • 批准号:
    8627238
  • 财政年份:
    2013
  • 资助金额:
    $ 52.57万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了